A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults

References

• Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab. 2015;66(Suppl. 1):8–16. doi: 10.1159/000370220
   PubMed Web of Science ®Google Scholar
• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590. doi: 10.1016/j.jid.2018.08.028
   PubMed Web of Science ®Google Scholar
• i SJ. Atopic dermatitis epidemiology: moving beyond cross-sectional studies. Br J Dermatol. 2019;181(5):883–884. doi: 10.1111/bjd.18440
   PubMed Web of Science ®Google Scholar
• Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther. 2022;12(12):2653–2668. doi: 10.1007/s13555-022-00819-6
   Web of Science ®Google Scholar
• Silverberg JI, Mohawk JA, Cirulli J, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. Dermat Contact Atopic Occup Drug. 2023;34(2):135–144. doi: 10.1089/derm.2022.29015.jsi
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66. doi: 10.1038/jid.2014.325
   PubMed Web of Science ®Google Scholar
• Eckert L, Gupta S, Amand C, et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the national health and wellness survey. J Am Acad Dermatol. 2017;77(2):274–279.e273. doi: 10.1016/j.jaad.2017.04.019
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Halling AS, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis—what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155–1162. doi: 10.1016/j.jaci.2022.12.002
   PubMed Web of Science ®Google Scholar
• Brunner PM, Suaãårez-Farinãéas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707. doi: 10.1038/s41598-017-09207-z
   PubMed Web of Science ®Google Scholar
• Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi: 10.2500/aap.2019.40.4202
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443
   PubMed Web of Science ®Google Scholar
• Mashiko S, Mehta H, Bissonnette R, et al. Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis. J Dermatol Sci. 2017;88(2):167–174. doi: 10.1016/j.jdermsci.2017.07.003
   PubMed Web of Science ®Google Scholar
• Salimi M, Barlow JL, Saunders SP, et al. A role for IL-25 and IL-33- driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210(13):2939–2950. doi: 10.1084/jem.20130351
   PubMed Web of Science ®Google Scholar
• Napolitano M, di Vico F, Ruggiero A, et al. The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis. Front Med. 2023;10:1165098. doi: 10.3389/fmed.2023.1165098
   Web of Science ®Google Scholar
• Davidson WF, Leung DYM, Beck LA, et al. Report from the national institute of allergy and infectious diseases workshop on “atopic dermatitis and the atopic march: mechanisms and interventions”. J Allergy Clin Immunol. 2019;143(3):894–913. doi: 10.1016/j.jaci.2019.01.003
   PubMed Web of Science ®Google Scholar
• Sugaya M. The role of Th17-related cytokines in atopic dermatitis. Int J Mol Sci. 2020;21(4):1314. doi: 10.3390/ijms21041314
   PubMed Web of Science ®Google Scholar
• McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75(1):38–50. doi: 10.1016/j.cyto.2015.05.023
   PubMed Web of Science ®Google Scholar
• Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75(1):14–24. doi: 10.1016/j.cyto.2015.05.010
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13–dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480–1489. doi: 10.1016/j.jid.2018.12.018
   PubMed Web of Science ®Google Scholar
• Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi: 10.1111/all.13954
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Maurelli M, Peris K, et al. Targeting IL-4 for the treatment of atopic dermatitis. Immunotargets Ther. 2020;9:151–156. doi: 10.2147/ITT.S260370
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
   PubMed Web of Science ®Google Scholar
• Leyva-Castillo JM, Das M, Artru E, et al. Mast cell-derived IL-13 downregulates IL-12 production by skin dendritic cells to inhibit the TH1 cell response to cutaneous antigen exposure. J Allergy Clin Immunol. 2021;147(6):2305–2315. e2303. doi: 10.1016/j.jaci.2020.11.036
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi: 10.1111/bjd.19574
   PubMed Web of Science ®Google Scholar
• Miron Y, Miller PE, Hughes C, et al. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022;150(3):690–700. doi: 10.1016/j.jaci.2022.01.028
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871.e11. doi: 10.1016/j.jaad.2018.01.017
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate- to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double- blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi: 10.1016/S0140-6736(20)30732-7
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898
   PubMed Web of Science ®Google Scholar
• Wan H, Jia H, Xia T, et al. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. 2022;35(9):e15636. doi: 10.1111/dth.15636
   PubMed Web of Science ®Google Scholar
• Szegedi K, Lutter R, Res PC, et al. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015;29(11):2136–2144. doi: 10.1111/jdv.13160
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi: 10.1016/j.jaci.2018.08.022
   PubMed Web of Science ®Google Scholar
• Tazawa T, Sugiura H, Sugiura Y, et al. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459–464. doi: 10.1007/s00403-004-0455-6
   PubMed Web of Science ®Google Scholar
• Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Rev Clin Immunol. 2021;17(1):15–25. doi: 10.1080/1744666X.2020.1858802
   PubMed Web of Science ®Google Scholar
• Graber P, Gretener D, Herren S, et al. The distribution of IL-13 receptor α1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4. Eur J Immunol. 1998;28(12):4286–4298. doi: 10.1002/(SICI)1521-4141(199812)28:12<4286:AID-IMMU4286>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• He H, Suryawanshi H, Morozov P, et al. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. J Allergy Clin Immunol. 2020;145(6):1615–1628. doi: 10.1016/j.jaci.2020.01.042
   PubMed Web of Science ®Google Scholar
• Minton K. What “drives” IL-4 versus IL-13 signalling? Nat Rev Immunol. 2008;8(3):167–167. doi: 10.1038/nri2283
   Web of Science ®Google Scholar
• Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018 Jun 7;9:888. doi: 10.3389/fimmu.2018.00888
   PubMed Web of Science ®Google Scholar
• Meng J, Li Y, Fischer MJM, et al. Th2 modulation of transient receptor potential channels: an unmet therapeutic intervention for atopic dermatitis. Front Immunol. 2021;12:696784. doi: 10.3389/fimmu.2021.696784
   PubMed Web of Science ®Google Scholar
• Oh MH, OH SY, Lu J, et al. TRPA1-dependent pruritus in IL-13-Induced chronic atopic dermatitis. J Immunol Baltim Md 1950. 2013;191(11):5371–5382. doi: 10.4049/jimmunol.1300300
   Google Scholar
• Ulzii D, Kido-Nakahara M, Nakahara T, et al. Scratching counteracts IL-13 signaling by upregulating the decoy receptor IL-13Rα2 in keratinocytes. Int J Mol Sci. 2019;20(13):3324. doi: 10.3390/ijms20133324
   PubMed Web of Science ®Google Scholar
• Brightling CE, Saha S, Hollins F. Interleukin-13: prospects for new treatments. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2010;40(1):42–49. doi: 10.1111/j.1365-2222.2009.03383.x
   PubMed Web of Science ®Google Scholar
• Mießner H, Seidel J, Smith ESt J. In vitro models for investigating itch. Front Mol Neurosci. 2022;15:984126. doi: 10.3389/fnmol.2022.984126
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(2):239–250. doi: 10.1111/jdv.15973
   PubMed Web of Science ®Google Scholar
• Wilson SR, Thé L, Batia LM, et al. The Epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155(2):285–295. doi: 10.1016/j.cell.2013.08.057
   PubMed Web of Science ®Google Scholar
• Zheng T, Oh M, Oh S, et al. Thymic stromal Lymphopoietin (TSLP) is involved in IL-13-Induced atopic dermatitis. J Allergy Clin Immunol. 2008;121(2):S271. doi: 10.1016/j.jaci.2007.12.1076
   Web of Science ®Google Scholar
• McKenzie GJ, Emson CL, Bell SE, et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity. 1998;9(3):423–432. doi: 10.1016/s1074-7613(00)80625-1
   PubMed Web of Science ®Google Scholar
• Punnonen J, de Vries JE. IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. J Immunol Baltim Md. 1994;152(3):1094–1102. 1950. doi: 10.4049/jimmunol.152.3.1094
   PubMed Web of Science ®Google Scholar
• Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch. Cell. 2021;184(2):422–440.e17. doi: 10.1016/j.cell.2020.12.033
   PubMed Web of Science ®Google Scholar
• Kim K, Kim H, Sung GY. An interleukin-4 and interleukin-13 induced atopic dermatitis human skin equivalent Model by a skin-on-A-Chip. Int J Mol Sci. 2022;23(4):2116. doi: 10.3390/ijms23042116
   PubMed Web of Science ®Google Scholar
• Furue K, Ito T, Tsuji G, et al. The IL‐13–OVOL1–FLG axis in atopic dermatitis. Immunology. 2019;158(4):281–286. doi: 10.1111/imm.13120
   PubMed Web of Science ®Google Scholar
• Howell MD, Boguniewicz M, Pastore S, et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol. 2006;121(3):332–338. doi: 10.1016/j.clim.2006.08.008
   PubMed Web of Science ®Google Scholar
• Nguyen JK, Austin E, Huang A, et al. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312(2):81–92. doi: 10.1007/s00403-019-01972-3
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99–106. doi: 10.1038/nm1332
   PubMed Web of Science ®Google Scholar
• Simpson EL, Guttman-Yassky E, Eichenfield LF, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition. Allergy. N/A(n/A). doi: 10.1111/all.15811
   Google Scholar
• Koppes SA, Brans R, Ljubojevic Hadzavdic S, et al. Stratum corneum tape stripping: monitoring of inflammatory mediators in atopic dermatitis patients using topical therapy. Int Arch Allergy Immunol. 2016;170(3):187–193. doi: 10.1159/000448400
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Rodriguez E, Stoãàlzl D, et al. Progression of acute-to- chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol. 2020;145(5):1406–1415. doi: 10.1016/j.jaci.2019.11.047
   PubMed Web of Science ®Google Scholar
• He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199–212. doi: 10.1016/j.jaci.2020.05.048
   PubMed Web of Science ®Google Scholar
• Tukler Henriksson J, Coursey TG, Corry DB, et al. IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in Cultured Conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2015;56(8):4186–4197. doi: 10.1167/iovs.14-15496
   PubMed Web of Science ®Google Scholar
• Thyssen JP, de Bruin-Weller MS, Paller AS, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy— international eczema council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33(7):1224–1231. doi: 10.1111/jdv.15608
   PubMed Web of Science ®Google Scholar
• Tollenaere MAX, Litman T, Moebus L, et al. Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin-13 and modulated by Tralokinumab in vitro. Acta Derm Venereol. 2021;101(4):adv00447. doi: 10.2340/00015555-3810
   PubMedGoogle Scholar
• Tollenaere MAX, Mølck C, Henderson I, et al. Tralokinumab effectively disrupts the IL-13/IL-13Rα1/IL-4Rα signaling complex but not the IL-13/IL-13Rα2 complex. JID Innov. 2023;3(5):100214. doi: 10.1016/j.xjidi.2023.100214
   PubMedGoogle Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–141. doi: 10.1016/j.jaci.2018.05.029
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–463. doi: 10.1111/bjd.19573
   PubMed Web of Science ®Google Scholar
• Simpson EL, Wollenberg A, Soong W, et al. Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3). Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2022;129(5):592–604.e5. doi: 10.1016/j.anai.2022.07.007
   PubMed Web of Science ®Google Scholar
• Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596–605. doi: 10.1001/jamadermatol.2023.0627
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Adam DN, Zirwas M, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022;23(4):547–559. doi: 10.1007/s40257-022-00702-2
   PubMed Web of Science ®Google Scholar
• Elewski BE, Ständer S, Zirwas M, et al. Early and sustained improvements in patient-reported outcomes with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis. Abstract presented at the Revolutionizing Atopic Dermatitis (RAD) Conference. Available from: https://revolutionizingad.com/images/resources/Dec2020VirtualConf/Abstracts/385_Elewski_et_al_RAD_PROs_Abstract.pdf
   Google Scholar
• Revolutionizing Atopic Dermatitis, 11-13 December 2021. Br J Dermatol. 2022 Apr;186(4):e135–e185. doi: 10.1111/bjd.21028
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Kabashima K, Pavel A, et al. 25854 effects on type 2 immunity when specifically targeting the interleukin-13 cytokine with tralokinumab. J Am Acad Dermatol. 2021;85(3):AB72. doi: 10.1016/j.jaad.2021.06.314
   Web of Science ®Google Scholar
• Bieber T, Beck LA, Pink A, et al. 28170 neutralizing interleukin-13 increases skin microbial diversity: results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis. J Am Acad Dermatol. 2021;85(3):AB177. doi: 10.1016/j.jaad.2021.06.722
   Web of Science ®Google Scholar
• Guttman-Yassky E, Pavel A, Kabashima K, et al. Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis. Exp Dermatol. 2021;30(S2):27–28. doi: 10.1111/exd.14341
   PubMedGoogle Scholar
• Silverberg JI, Barbarot S, Welzel J, et al. Tralokinumab prevents flares in moderate-to-severe atopic dermatitis: post hoc analyses of a randomized phase 3 clinical trial (ECZTRA 3). Abstract presented at the Revolutionizing Atopic Dermatitis (RAD) Conference. Available from: https://revolutionizingad.com/images/resources/Dec2020VirtualConf/Posters/375_RAD_2020_ECZTRA_3_Flares_Poster_7Dec2020.pdf
   Google Scholar
• Gutermuth J, Pink AE, Worm M, et al. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440–452. doi: 10.1111/bjd.20832
   PubMed Web of Science ®Google Scholar
• Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888–899. doi: 10.1111/bjd.21867
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473. doi: 10.1111/bjd.17869
   PubMed Web of Science ®Google Scholar
• Boever EHD, Ashman C, Cahn AP, et al. Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133(4):989–996.e4. doi: 10.1016/j.jaci.2014.01.002
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338. doi: 10.1183/09031936.00223411
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Beck LA, de Bruin Weller M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–465. doi: 10.1111/bjd.20810
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815–824. doi: 10.1016/j.jaad.2022.07.019
   PubMed Web of Science ®Google Scholar
• Warren RB, Reich K, Simpson EL, et al. 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN J Cutan Med. https://jofskin.org/index.php/skin/article/download/2028/1646
   Google Scholar
• Blauvelt A, Pink A, Worm M, et al. Outcomes of COVID-19 and vaccination in patients with moderate to severe atopic dermatitis treated with tralokinumab. JAMA Dermatol. 2022;158(11):1327–1330. doi: 10.1001/jamadermatol.2022.3488
   PubMed Web of Science ®Google Scholar
• Merola JF, Bagel J, Almgren P, et al. Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;85(1):71–78. doi: 10.1016/j.jaad.2021.03.032
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Naldi L. Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study. J Eur Acad Dermatol Venereol JEADV. 2023;37(5):e644–e645. doi: 10.1111/jdv.18753
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2021;21(1):21–40. doi: 10.1038/s41573-021-00266-6
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Gambardella A, Guanti M, et al. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: a multicenter, prospective, open-label case series study. J Am Acad Dermatol. 2023;89(2):430–432. doi: 10.1016/j.jaad.2023.04.056
   PubMed Web of Science ®Google Scholar
• Pereyra-Rodriguez JJ, Herranz P, Ruiz-Villaverde R, et al. Treatment of severe atopic dermatitis with tralokinumab in real clinical practice. Short-term effectiveness and safety results. Clin Exp Dermatol. Published online Apr 25, 2023;llad153. doi: 10.1093/ced/llad153
   Google Scholar
• García Castro R, Heras Mendaza F, Sánchez-Mateos DI S, et al. First short-term effectiveness and Security data of tralokinumab in severe atopic dermatitis in real clinical practice. Dermat Contact Atopic Occup Drug. Published online May 2, 2023. doi: 10.1089/derm.2023.0030
   Google Scholar
• Licata G, Tancredi V, Pezzolo E, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023;37(8):e1064–e1065. doi: 10.1111/jdv.19108
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Vignoli CA, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatol Treat. 2023;34(1):2216815. doi: 10.1080/09546634.2023.2216815
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Schena D, Gambardella A, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol JEADV. Published online Jul 22, 2023. doi: 10.1111/jdv.19382
   Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiderm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345
   PubMed Web of Science ®Google Scholar
• Damiani G, Calzavara-Pinton P, Stingeni L, et al. Italian guidelines for therapy of atopic dermatitis—adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019;32(6):e13121. doi: 10.1111/dth.13121
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030
   PubMed Web of Science ®Google Scholar
• Akhavan A, Rudikoff D. Atopic dermatitis: systemic immunosuppressive therapy. Semin Cutan Med Surg. 2008;27(2):151–155. doi: 10.1016/j.sder.2008.04.004
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Wollenberg A, Eichenfield LF, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with Dupilumab. Adv Ther. 2023;40(1):367–380. doi: 10.1007/s12325-022-02322-y
   PubMed Web of Science ®Google Scholar
• Sedeh FB, Henning MAS, Jemec GBE, et al. Comparative efficacy and safety of monoclonal antibodies and janus kinase inhibitors in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Acta Derm Venereol. 2022 Aug 24;102:adv00764. doi: 10.2340/actadv.v102.2075
   PubMed Web of Science ®Google Scholar